We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comorbidity in lung cancer: important but neglected. a review of the current literature.
- Authors
Grose, Derek; Devereux, Graham; Milroy, R
- Abstract
Treatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6% to 7% compared with 8% to 15% in other European countries and America. There also appear to be variations in treatment rates within Scotland. Although this variation in treatment and survival is popularly interpreted as evidence of variation in facilities, access to care, and clinical practice, it is possible that the increased comorbidity and poor performance status of the Scottish population may contribute to the observed disparities in treatment and outcomes, although this has never been proven. The demonstration that comorbidity influences treatment and survival rates will have important implications for the targeting of health services resources, screening, interpretation of cancer statistics, and the assessment and management of patients with lung cancer.
- Publication
Clinical lung cancer, 2011, Vol 12, Issue 4, p207
- ISSN
1938-0690
- Publication type
Journal Article
- DOI
10.1016/j.cllc.2011.03.020